title: A syngeneic variance library for functional annotation of human variation: application to BRCA2.
abstract: The enormous scope of natural human genetic variation is now becoming defined. To accurately annotate these variants, and to identify those with clinical importance, is often difficult to assess through functional assays. We explored systematic annotation by using homologous recombination to modify a native gene in hemizygous (wt/Deltaexon) human cancer cells, generating a novel syngeneic variance library (SyVaL). We created a SyVaL of BRCA2 variants: nondeleterious, proposed deleterious, deleterious, and of uncertain significance. We found that the null states BRCA2(Deltaex11/Deltaex11) and BRCA2(Deltaex11/Y3308X) were deleterious as assessed by a loss of RAD51 focus formation on genotoxic damage and by acquisition of toxic hypersensitivity to mitomycin C and etoposide, whereas BRCA2(Deltaex11/Y3308Y), BRCA2(Deltaex11/P3292L), and BRCA2(Deltaex11/P3280H) had wild-type function. A proposed phosphorylation site at codon 3291 affecting function was confirmed by substitution of an acidic residue (glutamate, BRCA2(Deltaex11/S3291E)) for the native serine, but in contrast to a prior report, phosphorylation was dispensable (alanine, BRCA2(Deltaex11/S3291A)) for BRCA2-governed cellular phenotypes. These results show that SyVaLs offer a means to comprehensively annotate gene function, facilitating numerical and unambiguous readouts. SyVaLs may be especially useful for genes in which functional assays using exogenous expression are toxic or otherwise unreliable. They also offer a stable, distributable cellular resource for further research.
authors.affiliation: The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA.
authors.forename: Tomas
authors.initials: T
authors.lastname: Hucl
authors.forename: Carlo
authors.initials: C
authors.lastname: Rago
authors.forename: Eike
authors.initials: E
authors.lastname: Gallmeier
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Brody
authors.forename: Myriam
authors.initials: M
authors.lastname: Gorospe
authors.forename: Scott E
authors.initials: SE
authors.lastname: Kern
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects / Q000528:radiation effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D043171:Chromosomal Instability / Q000187:drug effects / Q000528:radiation effects; D002999:Clone Cells; D019008:Drug Resistance, Neoplasm / Q000187:drug effects / Q000235:genetics; D005047:Etoposide / Q000494:pharmacology; D015723:Gene Library; D024522:Genes, BRCA2; D014644:Genetic Variation / Q000502:physiology*; D006801:Humans; D016685:Mitomycin / Q000494:pharmacology; D008954:Models, Biological; D016297:Mutagenesis, Site-Directed; D051135:Rad51 Recombinase / Q000235:genetics / Q000502:physiology; D014410:Tumor Stem Cell Assay
chemical_list: D000970:Antineoplastic Agents; D016685:Mitomycin; D005047:Etoposide; C495153:RAD51 protein, human; D051135:Rad51 Recombinase